PHILADELPHIA — Maintaining the ends of chromosomes, called telomeres, allows cells to continuously divide and achieve immortality. “Telomeres are much like the plastic cap on the ends of shoelaces -- they keep the ends of DNA from fraying,” said Roger Greenberg, MD, PhD, an associate professor of Cancer Biology in the Perelman School of Medicine at the University of Pennsylvania. In a new study published this week in Nature, senior author Greenberg and colleagues have developed a first-of-its- kind system to observe repair to broken DNA in newly synthesized telomeres, an effort that has implications for designing new cancer drugs.
Telomeres stay intact in most cancer cell types by means of a specialized enzyme called telomerase that adds the repetitive telomere DNA sequences to the ends of chromosomes. Cancer cells can also use a second method involving a DNA-repair-based mechanism, called alternative lengthening of telomeres, or ALT for short. In general, cancer cells take over either type of telomere maintenance machinery to become immortal. Overall, about fifteen percent of cancers (those of cartilage, bone, and brain, for example) use the ALT process for telomere lengthening and maintenance.
When DNA breaks, it triggers DNA repair proteins like the breast cancer suppressor proteins BRCA1 and BRCA2 into action, along with other helper proteins, that attach to the damaged stretch of DNA. These proteins stretch out the DNA, allowing it to be recognized by complementary sequences of telomere DNA. In general, this mechanism, called homologous recombination, happens when DNA building blocks are exchanged between two nearly identical molecules of DNA.
In the Nature study, the team found that telomeres use a unique type of repair to make new DNA, which they call “break-induced telomere synthesis.” The team found that the homologous recombination for telomeres was different from other forms of homologous recombination that involve BRCA1, 2 and Rad51 proteins, which are mutated in people with breast cancer and at risk for breast cancer.
“This is what we want to stop in cancer cells, but it has not been possible to directly follow the process while it is happening” Greenberg said. “This is the first study to follow all of the major steps of homologous recombination in real time. Now there is a possibility that because we know this process better, different points in the process could be interfered with to keep telomeres in cancer cells from continually lengthening. This may push them over the edge to cell death.”
Essential contributions to the study came from first and second authors Robert L. Dilley and Priyanka Verma, along with coauthors Nam Woo Cho, Harrison D. Winters, Anne R. Wondisford, from the department of Cancer Biology at Penn. Greenberg is also an associate investigator at the Abramson Family Cancer Research Institute and director of Basic Science for the Basser Center for BRCA.
: This work was supported by the National Institutes of Health (GM101149, CA138835, CA17494, T32GM007170, T32GM008216), the Abramson Family Cancer Research Institute and the Basser Center for BRCA.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.